سعر اكسارونت 5مجم 30 قرص 2024

Apixaban 5 mg film-coated tablets (Iksaront, Multi-Apex), an oral direct factor Xa inhibitor anticoagulant.

• Reduction of the risk of stroke and systemic embolism in adults with nonvalvular atrial fibrillation; prophylaxis of deep vein thrombosis after hip or knee replacement surgery; treatment of DVT and pulmonary embolism and reduction of the risk of recurrence after initial therapy.Population: AdultsDailyMed (US National Library of Medicine)
• Treatment of venous thromboembolism and reduction of the risk of recurrent VTE in pediatric patients from birth, after at least 5 days of initial anticoagulant treatment (weight-based dosing).Population: Pediatric patients from birthDailyMed (US National Library of Medicine)

• Most common adverse reactions (>1%) in adults are related to bleeding; in pediatric patients the most common (10% or more) were headache, vomiting and excessive menstrual bleeding.International label, same formulation · DailyMed (US National Library of Medicine)

• Active pathological bleeding; severe hypersensitivity reaction to apixaban (e.g. anaphylaxis).International label, same formulation · DailyMed (US National Library of Medicine)

• Boxed warning: premature discontinuation increases the risk of thrombotic events (consider alternative anticoagulation); epidural or spinal hematomas, possibly causing permanent paralysis, may occur with neuraxial anesthesia or spinal puncture.International label, same formulation · DailyMed (US National Library of Medicine)
• Can cause serious, potentially fatal bleeding (risk increased with antiplatelet agents, fibrinolytics, heparin, aspirin and chronic NSAID use); not recommended in patients with prosthetic heart valves or triple-positive antiphospholipid syndrome.International label, same formulation · DailyMed (US National Library of Medicine)

• Combined P-gp and strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, ritonavir)Increase apixaban exposure; reduce the dose by 50% for patients on 5 mg or 10 mg twice daily; avoid in patients already on 2.5 mg twice daily.DailyMed (US National Library of Medicine)
• Combined P-gp and strong CYP3A4 inducers (e.g. rifampin, carbamazepine, phenytoin, St John's wort)Decrease apixaban exposure; avoid concomitant use.DailyMed (US National Library of Medicine)
• Antiplatelet agents, fibrinolytics, heparin, aspirin, chronic NSAID useIncreased bleeding risk.DailyMed (US National Library of Medicine)

• Limited data are insufficient to inform drug-associated risks of major birth defects, miscarriage or adverse developmental outcomes; treatment may increase the risk of bleeding during pregnancy and delivery.International label, same formulation · DailyMed (US National Library of Medicine)
• No data on presence in human milk; apixaban is present in rat milk. Breastfeeding is not recommended during treatment.International label, same formulation · DailyMed (US National Library of Medicine)

• Apixaban: Selective, reversible inhibitor of free and clot-bound factor Xa and prothrombinase activity, decreasing thrombin generation and thrombus development (ELIQUIS US label).